Trump Strikes Deal with Japan, EU Next | Bloomberg Businessweek Daily 7/23/2025

Today's Bloomberg Businessweek Daily highlighted a new US-Japan trade deal featuring 15% tariffs and the White House's AI policy unveiling. Key corporate developments included a preview of Alphabet's earnings, Elon Musk's focus on Tesla's robotaxi program, and Carlsmed's successful IPO, which raised over $100 million for AI applications in spinal surgery.

Analysis

The market is facing a confluence of significant macroeconomic and sector-specific developments. The establishment of a new US-Japan trade deal with a 15% tariff rate introduces a tangible shift in trade policy, with further implications for global supply chains as negotiations with the EU are signaled to be next. Concurrently, the White House's unveiling of its AI policy vision introduces a layer of regulatory anticipation for the technology sector. Within this context, key large-cap tech names are at inflection points; Alphabet's upcoming earnings report is a critical event to watch, while Tesla's strategic focus is reaffirmed on its high-stakes robotaxi program. Underscoring the strong investor appetite for specific AI applications, the successful IPO of Carlsmed, a company using AI in spinal surgery, raised over $100 million, indicating robust capital flows into the specialized MedTech and AI space.

Key Decisions for Investors

• Investors should assess portfolio exposure to companies heavily reliant on US-Japan and US-EU trade in light of the new 15% tariff and anticipated negotiations.
• Monitor the specifics of the newly unveiled White House AI policy for potential regulatory impacts on major technology holdings like Alphabet and Tesla.
• Ahead of Alphabet's earnings, focus on management commentary regarding the impact of new AI regulations and any adjustments to forward guidance.
• For Tesla, the reaffirmed focus on the robotaxi program suggests investors should evaluate their position based on their conviction in the company's long-term autonomy strategy rather than short-term manufacturing metrics.
• The successful Carlsmed IPO highlights strong market appetite for niche AI applications, suggesting potential opportunities in specialized AI and MedTech companies beyond mega-cap tech.